Scientific publications

Lung Cancer Screening in People With COPD: The Pamplona-IELCAP Experience

Jan 3, 2024 | Magazine: Archivos de Bronconeumología

Juan P de-Torres  1 , Ana Belén Alcaide  2 , Arancha Campo  3 , Javier J Zulueta  4 , Gorka Bastarrika  5 , Ana Ezponda  5 , Miguel Mesa  6 , Diego Murillo  6 , María Rodriguez  7 , María Del Mar Ocón  2 , Carmen Felgueroso  2 , Jesús Pueyo  5 , María Dolores Lozano  8 , Luis M Montuenga  9 , Juan Berto  10 , María Teresa Perez-Warnisher  10 , Isberling Madeleine Di-Frisco  2 , Luis M Seijo  11

Introduction: The Global Initiative for Obstructive Lung Disease (GOLD) recommends lung cancer screening for patients with Chronic Obstructive Pulmonary Disease (COPD), but data is lacking regarding results of screening in this high-risk population. The main goal of the present work is to explore if lung cancer screening with Low Dose Chest Tomography (LDCT) in people with COPD, allows lung cancer (LC) diagnosis in early stages with survival compatible with curative state.

Methods: This is a post hoc exploratory analysis. Pamplona International Early Lung Cancer Action Program (P-IELCAP) participants with a GOLD defined obstructive pattern (post bronchodilator FEV1/FVC<0.70) were selected for analysis. The characteristics of those who developed LC and their survival are described. A Cox proportional analysis explored the factors associated with LC diagnosis.

Results: Eight hundred and sixty-five patients (77% male, 93% in spirometric GOLD stage 1+2) were followed for 102±63 months. LC prevalence was 2.6% at baseline, with an annual LC diagnosis rate of 0.68%. Early-stage tumors predominated (74%) with a median survival (25-75th percentiles) of 139 (76-185) months. Cumulative tobacco exposure, FEV1%, and emphysema were the main predictors of an LC diagnosis. Eight (11%) patients with COPD had a second LC, most of them in early stage (92%), and 6 (8%) had recurrence. Median survival (25-75th percentiles) in these patients was 168 (108-191) months.

Conclusions: Lung cancer screening of selected high-risk participants with COPD allowed the LC diagnosis in early stages with survival compatible with curative state.

CITATION  Arch Bronconeumol. 2024 Jan 3:S0300-2896(23)00417-9.  doi: 10.1016/j.arbres.2023.12.012